Aug. 21 at 3:09 PM
$GALT Excerpt from that July 2026 Liver Internation article: Current Therapeutic Mechanisms Are Not Fully Aligned with the Key Pathobiology of Stage F4c
Excerpt: "Many agents effective in nonācirrhotic MASH fail to achieve meaningful histological improvement in compensated cirrhosisā¦.As a result, improving metabolic abnormalities alone is often insufficient to produce substantial reversalā¦... Taken together, these observations suggest that current development strategies may not be fully aligned with the pathological features of stage F4c"
Galectin 3 inhibition and Belapectin is fully represented in this article.
Read it and draw your own conclusions as to our competitive landscape.
